Shanghai Yidi Biotechnology Co. Ltd. has synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase coupled to an androgen receptor targeting moiety via a linker reported ...

Herbicide development has slowed in recent years, but innovative research methods could soon drive significant progress in ...

Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to an androgen receptor targeting moiety through a linker acting as androgen ...

Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), ...

J.P. Morgan analyst Eric Joseph maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $30.00.

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

Here we explore peptide inhibitors of Cdc20, a substrate-recognition subunit and activator of the E3 ubiquitin ligase the anaphase promoting complex/cyclosome (APC/C) that is essential in mitosis and ...

Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), ...

First, that hybrid ubiquitin chains containing several linkage types play critical roles in regulating innate immune signalling networks; second that the essential roles of TRAF6 in initiating innate ...

Powered by a 9.2 kWh battery, it features three driving modes and TVS SmartXonnect™ technology for real-time navigation and diagnostics. TVS launches e3-wheeler, priced at Rs 2.95 lakh.